Chardan Capital analyst Keay Nakae reiterated a Hold rating on Ocugen (NASDAQ:OCGN) Inc on Thursday, setting a price target of $4.5, which is approximately 29.02% below the present share price of $6.34.
Nakae expects Ocugen Inc to post earnings per share (EPS) of -$0.04 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Ocugen, with an average price target of $7.88.
The analysts price targets range from a high of $11 to a low of $4.5.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$7.06 million. The company's market cap is $1.26 billion.
According to TipRanks.com, Chardan Capital analyst Keay Nakae is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 25.8% and a 50.60% success rate.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.